Adar1 Capital Management
$2.1B 13F equity value
331 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Adar1 Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ABVX | ABIVAX SA | 1,804,703 | $240M | 11.4% |
| PTGX | PROTAGONIST THERAPEUTICS INC | 960,863 | $118M | 5.6% |
| ROIV | ROIVANT SCIENCES LTD | 3,157,008 | $112M | 5.3% |
| SPY | STATE STR SPDR S&P 500 ETF T | 129,087 | $96M | 4.6% |
| IMVT | IMMUNOVANT INC | 2,330,716 | $90M | 4.3% |
| ZLAB | ZAI LAB LTD | 3,369,034 | $64M | 3.0% |
| AGIO | AGIOS PHARMACEUTICALS INC | 1,288,053 | $48M | 2.3% |
| CRNX | CRINETICS PHARMACEUTICALS IN | 1,222,080 | $46M | 2.2% |
| BOXX | EA SERIES TRUST | 337,125 | $39M | 1.9% |
| CYTK | CYTOKINETICS INC | 457,907 | $39M | 1.8% |
Track Adar1 Capital Management's 13F portfolio: $2.1B in reported holdings, 331 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}